Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer

[1] Ismail-Khan R(2010)A review of triple-negative breast cancer Cancer Control 17 173-176

[2] Bui MM(2012)Update on triple-negative breast cancer: prognosis and management strategies Int J Womens Health 4 511-520

[3] Brouckaert O(2007)Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429-4434

[4] Wildiers H(2012)Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy Expert Opin Ther Targets 16 103-119

[5] Floris G(2016)Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy Ther Adv Med Oncol 8 48-56

[6] Neven P(2016)MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy Drug Des Dev Ther 10 43-52

[7] Dent R(2017)Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials Curr Med Res Opin 33 1663-1675

[8] Trudeau M(2015)MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model Mol Cancer Ther 14 2773-2781

[9] Pritchard KI(2015)Comprehensive two- and three-dimensional RNAi screening identifies PI3K inhibition as a complement to MEK inhibitor AS703026 for combination treatment of triple-negative breast cancer J Cancer 6 1306-1319

[10] Hanna WM(2010)E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration J Pharmacol Exp Ther 335 23-31

[1] Ismail-Khan R(2010)A review of triple-negative breast cancer Cancer Control 17 173-176

[2] Bui MM(2012)Update on triple-negative breast cancer: prognosis and management strategies Int J Womens Health 4 511-520

[3] Brouckaert O(2007)Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429-4434

[4] Wildiers H(2012)Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy Expert Opin Ther Targets 16 103-119

[5] Floris G(2016)Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy Ther Adv Med Oncol 8 48-56

[6] Neven P(2016)MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy Drug Des Dev Ther 10 43-52

[7] Dent R(2017)Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials Curr Med Res Opin 33 1663-1675

[8] Trudeau M(2015)MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model Mol Cancer Ther 14 2773-2781

[9] Pritchard KI(2015)Comprehensive two- and three-dimensional RNAi screening identifies PI3K inhibition as a complement to MEK inhibitor AS703026 for combination treatment of triple-negative breast cancer J Cancer 6 1306-1319

[10] Hanna WM(2010)E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration J Pharmacol Exp Ther 335 23-31